Pegademase bovine
Adagen (pegademase bovine) is an enzyme pharmaceutical. Pegademase bovine was first approved as Adagen on 1990-03-21. It is used to treat severe combined immunodeficiency in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pegademase bovine
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Adagen | pegademase bovine | Leadiant Biosciences | N-19818 DISCN | 1990-03-21 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
pegademase bovine, Adagen, Leadiant Biosciences, Inc | |||
| 2097-03-21 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J2504 | Injection, pegademase bovine, 25 iu |
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | 1 | 1 | — | 1 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoid tumor | D002276 | D3A.00 | 1 | 1 | — | — | — | 2 | |
| Multiple myeloma | D009101 | C90.0 | — | 1 | — | — | — | 1 | |
| Papillary thyroid cancer | D000077273 | — | 1 | — | — | — | 1 | ||
| Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | — | — | — | 1 | |
| Dumping syndrome | D004377 | EFO_1001307 | K91.1 | — | 1 | — | — | — | 1 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | 1 | — | — | — | 1 |
| Intraductal carcinoma noninfiltrating | D002285 | D05.1 | 1 | 1 | — | — | — | 1 | |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Acromegaly | D000172 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 2 | — | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
| Breast carcinoma in situ | D000071960 | D05 | 1 | — | — | — | — | 1 | |
| Phenylketonurias | D010661 | E70.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PEGADEMASE BOVINE |
| INN | — |
| Description | Adagen (pegademase bovine) is an enzyme pharmaceutical. Pegademase bovine was first approved as Adagen on 1990-03-21. It is used to treat severe combined immunodeficiency in the USA. |
| Classification | Enzyme |
| Drug class | enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201514 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 194 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,272 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more